Dermatological Reviews最新文献

{"title":"Regulatory, Ethical, and Safety Considerations of Exosome-Based Therapies in Dermatology","authors":"Sawyeh Maher,&nbsp;Michael H. Gold","doi":"10.1002/der2.70071","DOIUrl":"https://doi.org/10.1002/der2.70071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Exosome and stem cell–derived products have rapidly gained popularity in dermatology, particularly in elective settings. Despite their expanding clinical and commercial use, exosome-based therapies have yet to receive regulatory approval for dermatologic indications, and long-term safety data remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To review the biological background, global regulatory frameworks, safety considerations, and ethical challenges associated with exosome-based therapies in dermatology, with an emphasis on clinical decision-making in elective settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A narrative review of current regulatory guidance, published clinical and preclinical literature, and ethical frameworks relevant to exosome and stem cell–derived products was conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Exosome-based therapies do demonstrate potential regenerative applications in areas such as skin rejuvenation, wound healing, and hair restoration. However, substantial variability in cell sourcing, manufacturing processes, and product characterization makes standardization and regulation complicated. No exosome-based products have received U.S. Food and Drug Administration (FDA) approval for dermatologic use. Reported adverse reactions, limited longitudinal follow-up, and variability in international regulatory oversight highlight persistent translational and safety gaps.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While exosome-based therapies represent an evolving frontier in dermatology, their integration into clinical practice should proceed with caution. Regulatory literacy, transparent informed consent, structured product evaluation, and evidence-based clinical restraint are essential to ensure patient safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Biogenesis to Bedside: Sources, Isolation and Detection, Formulation Purity, and the Current Limits of Exosome‑Based Drug Delivery","authors":"Rachel Sharon Dias,&nbsp;Guhaneshram V.,&nbsp;Shreeya Nayak,&nbsp;Neha Akhoon,&nbsp;Abdul Mannan Faruk Ahmed,&nbsp;Sohil Khan,&nbsp;Mohammed Salim Karattuthodi,&nbsp;Aseem Sharma","doi":"10.1002/der2.70065","DOIUrl":"https://doi.org/10.1002/der2.70065","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Exosome-based skin boosters are increasingly recognized in aesthetic dermatology, yet consolidated evidence on their safety and effectiveness remains limited. This scoping review aimed to synthesize available evidence on the clinical safety, efficacy, and practical application of exosome-based skin boosters for facial rejuvenation in aesthetic medicine settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of PubMed, Scopus, and Embase (2015–2025) was conducted following PRISMA-ScR guidelines. Inclusion criteria focused on clinical trials or observational studies evaluating exosome-based products for facial skin rejuvenation. Primary outcomes assessed were adverse events and clinical efficacy measures (skin texture, wrinkles, pigmentation, and global aesthetic improvement).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight studies (<i>n</i> = 20–60 participants per study, predominantly female, age range 18–80 years) met inclusion criteria. Exosomes from platelets, stem cells, adipose tissue, and bovine milk were delivered topically, via microneedling, or with laser assistance. All products demonstrated favorable tolerability; mild, transient adverse effects (erythema, dryness, petechiae) resolved within 2–14 days without serious complications. Efficacy improvements were reported across studies: skin texture enhancement (76.8%–90.9%), wrinkle reduction (5-85.5% improvement), and melasma clearance (up to 99% melanin index reduction).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Exosome-based skin boosters appear safe and effective for facial rejuvenation with minimal adverse effects. However, heterogeneous study designs, small sample sizes, and short follow-up periods necessitate larger, standardized clinical trials with extended monitoring to validate long-term safety and establish treatment protocols for broader clinical application.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-, Pro-, Post-, and Synbiotics for Skin Health: A Narrative Review of Cosmetic and Dermatological Applications","authors":"Guilherme Carvalho Tavares da Silva,&nbsp;Kátia de Pádua Silva,&nbsp;Ana Carolina Furian da Silva,&nbsp;Larissa Pavanello,&nbsp;Gabriela de Moraes Saqui,&nbsp;Andréa Fernandes Eloy Costa da França,&nbsp;Gislaine Ricci Leonardi,&nbsp;Karina Cogo-Müller","doi":"10.1002/der2.70070","DOIUrl":"https://doi.org/10.1002/der2.70070","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Prebiotics, probiotics, postbiotics, and synbiotics have been increasingly investigated and incorporated into cosmetic formulations to preserve or restore skin health, function, and esthetics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To review biotics applications in cosmetology, discussing their concepts, general characteristics, and potential benefits and limitations in modulating the skin microbiome and improving skin health.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>Literature searches were conducted on the PubMed, Web of Science, and Scopus databases to identify studies evaluating the role of biotics in skin health and dermatological applications. No language restrictions were applied, and studies published up to April 2025 were considered. Full-text in vitro, in vivo, and clinical studies investigating topical prebiotics, probiotics, postbiotics, or synbiotics were included. Abstracts, reviews, editorials, letters, meta-analyses, and conference proceedings were excluded. Analysis covered biotic category, study design, and microbiological and tissue-related outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review sample included 60 studies. In vitro and in vivo evidence indicates that prebiotics, postbiotics, and synbiotics can reduce potentially pathogenic microorganisms, including <i>Staphylococcus aureus</i>, <i>Cutibacterium acnes</i>, and <i>Corynebacterium</i> spp., without negatively affecting—or in some cases promoting—the growth of commensal bacteria such as <i>Staphylococcus epidermidis</i>. Most studies reported antioxidant, anti-inflammatory, and antimelanogenic effects, in addition to improvements in skin hydration and anti-aging parameters. However, clinical evidence supporting the efficacy and safety of these compounds, particularly in disease-related conditions, remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Further research, especially well-designed in vivo and clinical studies, is needed to elucidate the long-term effects, benefits, and limitations of biotics application on the skin and its microbiome. Despite their widespread use in cosmetic products, an evidence-based approach is essential to ensure the efficacy and safety of biotic-based formulations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147567405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information Gaps and Practical Barriers in the Recommendation of Cosmetic Products by Dermatologists: Evidence From a Brazilian Study","authors":"Cristina Wöhlke Vendruscolo,&nbsp;Edileia Bagatin,&nbsp;Gislaine Ricci Leonardi","doi":"10.1002/der2.70059","DOIUrl":"https://doi.org/10.1002/der2.70059","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The recommendation of cosmetic products in dermatological practice has become increasingly common, driven by the evolution of formulations and active ingredients that sometimes mirror pharmacological effects. This convergence has blurred the boundaries between cosmetics and medications, creating uncertainty among professionals regarding product efficacy and classification. Additionally, dermatologists face challenges interpreting label information, which is often technical, fragmented, or lacks standardization, undermining clarity and clinical confidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate dermatologists' understanding of the labeling information on cosmetic products they prescribe or recommend.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Structured interviews were conducted with 118 Brazilian dermatologists using a 29-question instrument (multiple-choice, open-ended, and scaled formats). Descriptive analysis was performed using specific statistical software¹.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most participants regularly prescribe cosmetics or dermocosmetics and value labeling information. However, they report difficulties interpreting data and defining terms such as “claim” and “natural product.” Industry communication, particularly via medical detailing (industry representatives) and congresses, strongly influences prescribing decisions. There is a clear demand for objective information on composition, active concentration, safe use, and scientific evidence of efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Participants suggested improving communication between the cosmetics industry and dermatologists by providing clear, standardized information on ingredients, concentrations, usage guidelines, efficacy, adverse effects, and safety during pregnancy. These findings reinforce the need for tools that support informed clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AestheFill® in Aesthetic Medicine: From Materials Science to Clinical Practice","authors":"Jui-Yu Lin,&nbsp;Chuan-Yuan Lin","doi":"10.1002/der2.70068","DOIUrl":"https://doi.org/10.1002/der2.70068","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Injectable poly-D,<span>l</span>-lactic acid (PDLLA; AestheFill®) is a collagen-stimulating biostimulator increasingly used for facial rejuvenation and skin-quality improvement. AestheFill® consists of porous PDLLA microspheres suspended in sodium carboxymethylcellulose (CMC), a formulation that influences handling, early volumization, and tissue integration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To summarize the composition, mechanisms, reconstitution/dilution methods, clinical efficacy and safety, complication prevention/management, and practical comparisons relevant to AestheFill®.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Narrative review of preclinical studies, clinical trials, case reports, and consensus/guideline publications addressing AestheFill® properties, in vivo tissue responses, clinical outcomes, and adverse-event management, informed by structured database searching and reference-list screening, with emphasis on clinically actionable preparation and injection protocols.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Preclinical evidence shows localized persistence of PDLLA microspheres at the intended plane with progressive cellular infiltration and type I collagen deposition, supporting a scaffold-to-tissue replacement mechanism. Randomized evaluator-blinded comparative trials in South Korea and China demonstrate noninferior nasolabial fold correction versus hyaluronic acid comparators with favorable short- and long-term safety. Outcomes are technique-dependent: initial reconstitution should use sterile water for injection to ensure complete CMC hydration; suspension thickness should be selected according to injection plane; and injections should be delivered as small, evenly distributed aliquots to reduce maldistribution-related nodules. Accelerated reconstitution techniques (back-and-forth and vacuum-assisted hydration variants) improve workflow and suspension homogeneity. Recent guidance emphasizes ultrasonography-assisted diagnosis and staged management for AestheFill® nodules. Rarely, vascular occlusion may cause severe ocular or neurologic sequelae.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Available evidence supports injectable PDLLA as a collagen-stimulating filler when reconstitution and anatomy-driven technique are standardized; further comparative trials and standardized outcomes are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copper Peptides in Regenerative Aesthetic Dermatology","authors":"Raheleh Sarbaziha,&nbsp;David J. Goldberg","doi":"10.1002/der2.70067","DOIUrl":"https://doi.org/10.1002/der2.70067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Regenerative medicine has expanded rapidly over the past decade, with continued exponential growth across both clinical and aesthetic applications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Understand the use of GHK-Cu (copper peptide), a peptide that has emerged as one of the most widely recognized and clinically relevant peptides due to its versatility in administration, favorable safety profile, and broad therapeutic potential.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Materials</h3>\u0000 \u0000 <p>This review article will explore the rise of GHK-Cu within regenerative aesthetics and review the evidence supporting its benefits in skin health, repair, and rejuvenation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Conclusion</h3>\u0000 \u0000 <p>Peptides—administered via injectable, topical, intravenous, and intranasal routes—have become a central component of modern regenerative therapies and integrative aesthetic practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147562594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collagenase Inhibitory Activities of Plants: A Review","authors":"Nelum Priyadarshani Piyasena,&nbsp;Ayeshmanthi Jayasekara,&nbsp;Mayuri Napagoda,&nbsp;Nimal Adikaram,&nbsp;Lalith Jayasinghe","doi":"10.1002/der2.70064","DOIUrl":"https://doi.org/10.1002/der2.70064","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Aging is a dynamic, gradual, and irreversible biological process, with skin aging characterized by dermal thinning, a progressive loss of collagen fibers, and a reduction in elastic fibers, ultimately leading to lost skin elasticity and firmness. Reducing damage to cellular components over time and enhancing tissue morphology helps maintain youthful-looking skin. Even though skin aging is inevitable, skincare formulations could help delay its progression to some extent. There is a steady increase in public awareness about the health benefits of plant-derived and other natural ingredients in skincare formulations, as well as concerns about the risks of synthetic chemicals. The cosmetics industry is paying more attention to natural products as a result.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This review aims to provide a concise overview of current research on natural collagenase inhibitors and their relevance in anti-aging skincare.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Given that natural collagenase inhibitors are crucial in the development of anti-aging skincare products, this review aims to provide a concise overview of the current literature on the potential collagenase inhibitory activities of herbs, fruits, and marine algae, as well as their secondary phytoconstituent compounds and potential applications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The compiled information provides a valuable foundation for further in-depth research aimed at supporting the development of plant-based skincare formulations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147288371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Janus kinases: Targeted Cytokine and Kinase Modulators for Refractory Vitiligo","authors":"E. Ip,&nbsp;M. Rodrigues","doi":"10.1002/der2.70057","DOIUrl":"https://doi.org/10.1002/der2.70057","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Refractory vitiligo encompasses disease unresponsive to conventional medical therapies and phototherapy, presenting a significant clinical challenge. Treatment resistance stems from multiple interconnected mechanisms. While JAK inhibitors represented a paradigm shift by targeting interferon-γ-driven pathophysiology, substantial limitations persist. This review aims to evaluate emerging therapeutic strategies beyond JAK inhibitors that address the multifaceted pathophysiology of refractory vitiligo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This review covers a broad range of studies, including in vitro and in vivo research, with a focus on therapeutic advancements beyond JAK inhibitors for refractory vitiligo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Strategic targeting of immune memory through IL-15/CD122 blockade, chemokine pathways via CXCL10 and CXCR3 antagonism, epigenetic regulation through BET protein inhibition, and melanocyte regeneration via mTOR modulation, prostaglandin therapy, melanocortin receptor activation, and Wnt pathway agonists represents a paradigm shift from single-pathway interventions. While most of these novel agents remain in preclinical or early-phase clinical trials, their mechanistically diverse approaches collectively offer a comprehensive therapeutic framework that addresses both persistent immune-mediated melanocyte destruction and regenerative insufficiency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among emerging therapies, IL-15/CD122 blockade shows particular promise by targeting tissue-resident memory T cells to potentially achieve durable repigmentation. Concurrently, afamelanotide, now in Phase III trials, offers a complementary regenerative approach by stimulating melanocyte proliferation through melanocortin receptor activation. Together, these mechanistically distinct strategies may overcome the immune memory and stem cell depletion that characterizes treatment-refractory disease. These advances offer exciting new possibilities for patients with refractory vitiligo.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146680307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bonding Beyond Sutures: Exploring Skin Glue in Mohs Micrographic Surgery","authors":"Aysham Chaudry,&nbsp;Braden Van Alfen,&nbsp;Faraz Yousefian","doi":"10.1002/der2.70063","DOIUrl":"https://doi.org/10.1002/der2.70063","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cyanoacrylate tissue adhesives (CTAs) have emerged as a valuable adjunct or possible alternative to sutures for wound closure in Mohs micrographic surgery (MMS). This review explores their utility, highlighting advantages such as reduced operative time, enhanced patient satisfaction, and comparable safety profiles to traditional sutures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A search of PubMed was conducted in 2025 using the terms “Mohs micrographic surgery, cyanoacrylate, and tissue adhesive.” Articles with relevant, novel information were included in this practical review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>CTAs offer several advantages, including a significant reduction in operative time and enhanced patient satisfaction. They also have comparable safety profiles to traditional sutures regarding infection, bleeding, and wound dehiscence. Novel applications, including stabilizing skin grafts, flaps, and friable tissue specimens, underscore their versatility. Despite these benefits, limitations such as reduced tensile strength, cost, and contraindications in select patient populations warrant careful consideration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Continued research into optimizing CTA formulations and applications may expand their role in MMS and dermatologic surgery, enhancing both clinical efficiency and cosmetic outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Treatments Compared to Traditional Therapies in Managing Childhood Eczema in Terms of Efficacy and Safety","authors":"Kathleen Ward,&nbsp;Daniela Rizzo,&nbsp;Valerie Foy,&nbsp;Zelma Chiesa Fuxench","doi":"10.1002/der2.70062","DOIUrl":"https://doi.org/10.1002/der2.70062","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder that often begins in early childhood and significantly impacts quality of life. While traditional management has centered on topical corticosteroids, emollients, and calcineurin inhibitors, the therapeutic landscape has rapidly expanded to include systemic immunomodulators, biologics, and targeted small molecules. This literature review aims to compare the efficacy and safety of traditional therapies with emerging treatment options for pediatric AD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A PubMed search identified articles on novel and traditional AD therapies in children ≤ 18 years in terms of safety and efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Topical corticosteroids and emollients remain first-line therapies for mild-to-moderate disease, with demonstrated efficacy in reducing inflammation and restoring skin barrier function. Calcineurin inhibitors offer a steroid-sparing alternative. Newer topical agents like crisaborole (PDE4 inhibitor) and ruxolitinib (JAK1/2 inhibitor) provide targeted anti-inflammatory effects with favorable safety profiles. For moderate-to-severe or refractory cases, systemic therapies—including cyclosporine, methotrexate, and the IL-4Rα antagonist dupilumab—offer robust disease control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While newer therapies demonstrate promising efficacy and tolerability, long-term safety data in pediatric populations are still evolving. Treatment decisions should be individualized based on disease severity, age, comorbidities, and caregiver preferences. This review synthesizes current evidence to guide clinicians in selecting safe and effective therapies for childhood AD across the disease spectrum. The evidence base for pediatric AD is relatively limited, with much of the available data extrapolated from adult populations. Many trials were short-term, which does not fully capture the chronic relapsing nature of AD or the long-term safety of emerging therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}